ArticleBMC ophthalmology2026
Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo report a rare and instructive case of intraocular inflammation following intravitreal Faricimab (Vabysmo) injection that progressed to anterior scleritis despite early intervention. While Faricimab is widely used for neovascular age-related macular degeneration (nAMD), understanding its potential for delayed, progressive inflammatory complications is crucial for clinical vigilance. CASE PRESENTATION: A 74-year-old Asian male with nAMD developed intraocular inflammation following his fifth intravitreal injection of Faricimab, after four prior uneventful injections. The patient initially presented with corneal edema, anterior uveitis, and elevated intraocular pressure (IOP). Although initial treatment with topical corticosteroids and IOP-lowering agents led to partial improvement, the inflammation subsequently progressed, manifesting as persistent vitritis and the development of anterior scleritis. Escalation to systemic corticosteroid therapy was required, which resulted in complete resolution of the inflammation. Faricimab was permanently discontinued, and the patient was successfully switched to Aflibercept (Eylea) without further complications.
conclusionsThis case highlights that initially mild anterior segment inflammation following Faricimab injection can progress to more severe ocular inflammation, such as scleritis, despite early topical therapy. Clinicians should maintain close monitoring and a low threshold for escalating to systemic treatment to achieve complete resolution and safeguard visual outcomes.
Indexed as
Identifiers
42920111What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.